Sponsor

Pakistan Institute of Living and Learning

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Pakistan Institute of Living and Learning appears in 18 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials18
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

18 shown
Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in PakistanNCT07015944 · lead sponsor · 2025-06-13
RECRUITING
Culturally Adapted Psychosocial Interventions for Early Psychosis in a Low-resource SettingNCT05814913 · lead sponsor · 2024-04-15
RECRUITING
Individual Placement and Support and/or Cognitive Remediation Therapy Added to TAU in Patients With Early SchizophreniaNCT03974620 · lead sponsor · 2024-12-01
UNKNOWN
Learning Through Play Plus for PsychosisNCT06301347 · lead sponsor · 2024-04-01
UNKNOWN
Cognitive Behavior Therapy (CBT) Informed Mobile-Application for First Episode PsychosisNCT05567575 · lead sponsor · 2022-10-01
UNKNOWN
Measurement-Based Care Vs. Standard Care for Major Depressive DisorderNCT05431374 · lead sponsor · 2022-09-01
COMPLETED
Minocycline Augmentation of Clozapine for Treatment Resistant SchizophreniaNCT02533232 · lead sponsor · 2022-08-30
UNKNOWN
Moving on After Breast Cancer Plus- for Breast Cancer SurvivorsNCT03571984 · lead sponsor · 2019-03-10
COMPLETED
Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.NCT03435744 · lead sponsor · 2019-01-01
COMPLETED
Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.NCT03510741 · lead sponsor · 2019-01-01
COMPLETED
Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental StatesNCT02569307 · lead sponsor · 2015-10-01
COMPLETED
RCT of Methotrexate Added to Treatment As Usual in SchizophreniaNCT02074319 · lead sponsor · 2013-12-01
COMPLETED
Culturally Adapted Cognitive Behavior Therapy for Psychosis in PakistanNCT02202694 · lead sponsor · 2012-03-01
COMPLETED
Culturally Adapted Family Intervention For PsychosisNCT02167347 · lead sponsor · 2012-02-01
COMPLETED
Randomized Double Blind Placebo Control Study in Patients with SchizophreniaNCT01602029 · lead sponsor · 2010-08-01
COMPLETED
Role of Anti-Inflammatory Agents in Patients With SchizophreniaNCT00929955 · lead sponsor · 2009-06-01
COMPLETED
Prescribing the Right Agent for Depression in Adults (PRADA): a Double-blind, Randomised Controlled Trial Using a Web-based Multi-modal Clinical Decision Support System and Genetic Information to Personalise Antidepressant Treatment in Diverse Clinical Settings Across the GlobeNCT07796295 · collaborator · 2026-10-01
NOT_YET_RECRUITING
Role of Minocycline in First Episode PsychosisNCT00916461 · collaborator · 2006-05-01
COMPLETED

Drugs studied in this sponsor's trials

9 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Pakistan Institute of Living and Learning as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
placebo5
minocycline3
ondansetron2
simvastatin2
acetylcysteine1
methotrexate1
omega-3 fatty acids1
simvastatin 20 MG1

Sponsor roles

lead sponsor16
collaborator2
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.